Ovarian Cancer Radiosensitivity: What Have We Understood So Far?

Barcellini, Amelia; Charalampopoulou, Alexandra; De Cecco, Loris; Fodor, Andrei; Rabaiotti, Emanuela; Candotti, Giorgio; Secondino, Simona; Facoetti, Angelica; Locati, Laura Deborah; Pignata, Sandro; Orlandi, Ester; Mangili, Giorgia.

Afiliação

Barcellini A; Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), 27100 Pavia, Italy.
Charalampopoulou A; Department of Internal Medicine and Medical Therapy, University of Pavia, 27100 Pavia, Italy.
De Cecco L; Radiobiology Unit, Research and Development Department, National Center for Oncological Hadrontherapy (CNAO), 27100 Pavia, Italy.
Fodor A; Molecular Mechanisms Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, 20133 Milan, Italy.
Rabaiotti E; Department of Radiation Oncology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Candotti G; Unit of Gynaecology and Obstetrics, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Secondino S; Unit of Gynaecology and Obstetrics, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Facoetti A; Medical Oncology Unit, IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
Locati LD; Radiobiology Unit, Research and Development Department, National Center for Oncological Hadrontherapy (CNAO), 27100 Pavia, Italy.
Pignata S; Department of Internal Medicine and Medical Therapy, University of Pavia, 27100 Pavia, Italy.
Orlandi E; Translational Oncology Unit, Maugeri Clinical Research Institutes IRCCS, 27100 Pavia, Italy.
Mangili G; Department of Urology and Gynecology, Istituto Nazionale Tumori, IRCCS-Fondazione G. Pascale Napoli, 80131 Naples, Italy.

Life (Basel) ; 13(1)2022 Dec 20.

Article em En | MEDLINE | ID: mdl-36675955

ABSTRACT

Radiotherapy has been increasingly considered as an active treatment to combine with other approaches (i.e., surgery, chemotherapy, and novel target-based drugs) in ovarian cancers to palliate symptoms and/or to prolong chemotherapy-free intervals. This narrative review aimed to summarize the current knowledge of the radiosensitivity/radioresistance of ovarian cancer which remains the most lethal gynecological cancer worldwide. Indeed, considering the high rate of recurrence in and out of the radiotherapy fields, in the era of patient-tailored oncology, elucidating the mechanisms of radiosensitivity and identifying potential radioresistance biomarkers could be crucial in guiding clinical decision-making.

Palavras-chave

ovarian cancer; radiation; radiobiology; radioresistance; radiosensitivity

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article